The effects of SCH 351125 on mononuclear cell trafficking to joints, synovial inflammation and expression of chemokines in subjects with rheumatoid arthritis
| ISRCTN | ISRCTN87502236 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN87502236 |
| Secondary identifying numbers | P03653 |
- Submission date
- 23/08/2007
- Registration date
- 23/08/2007
- Last edited
- 29/08/2007
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof P.P. Tak
Scientific
Scientific
Academic Medical Centre (AMC)
Department of Clinical Immunology and Rheumatology
P.O. Box 22660
Amsterdam
1100 DD
Netherlands
| Phone | +31 (0)20 566 2171 |
|---|---|
| p.p.tak@amc.nl |
Study information
| Study design | Randomised, double-blind, placebo controlled, parallel group trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study objectives | SCH 351125 50 mg twice daily (BID) 2/days is an effective treatment for Rheumatoid Arthritis (RA). Primary objectives of the study are to determine the effects of SCH 351125 on mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis, and to evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg BID in subjects with rheumatoid arthritis when administered for 28 days. |
| Ethics approval(s) | Ethics approval received from the Medical Ethics Committee of the Academic Medical Centre (University of Amsterdam) on the 21st January 2004 (ref: 03/267). |
| Health condition(s) or problem(s) studied | Rheumatoid arthritis |
| Intervention | Subjects with active Rheumatoid Arthritis (RA) were enrolled in a randomised double-blind, placebo-controlled, parallel-group study exposed to either SCH 351125 50 mg BID or matched placebo, in a 2:1 ratio, for 28 days. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | SCH 351125 |
| Primary outcome measure | 1. To determine the effects of SCH 351125, a CCR5 receptor antagonist, on mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis 2. To evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg twice-daily in subjects with rheumatoid arthritis when administered for 28 days |
| Secondary outcome measures | 1. To explore the effects of SCH 351125 on: 1.1. Synovial inflammation via MRI 1.2. Chemokine expression and concentrations in the plasma, synovial tissue and synovial fluid (messenger Ribonucleic Acid [mRNA] expression only) 1.3. Mononuclear cell concentrations in the peripheral blood 1.4. Clinical signs and symptoms of rheumatoid arthritis 1.5. To determine the single-dose and multiple dose pharmacokinetic profile of SCH 351125 in subjects with rheumatoid arthritis |
| Overall study start date | 01/03/2004 |
| Completion date | 01/05/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 30 |
| Key inclusion criteria | 1. Subjects 18 to 70 years of age, of either sex, and of any race 2. Diagnosis of RA according to the American College of Rheumatology (ACR) criteria, for at least six weeks prior to entry in the study 3. Active RA defined as: 3.1. Three or more tender joints 3.2. Three or more swollen joints, and 3.3. At least one of the following three: 3.3.1. Duration of morning stiffness equal to or greater than 45 minutes 3.3.2. Erythrocyte sedimentation rate equal to or greater than 28 mm/hour 3.3.3. C-reactive protein equal to or greater than 10 mg/L 4. Functional class I, II or III 5. Subjects must be free of any clinically significant disease (other than rheumatoid arthritis) that would interfere with the study evaluations and/or safety 6. Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules 7. Females must not be breast-feeding, and either be of non-childbearing potential (i.e., sterilised via hysterectomy or bilateral tubal ligation or at least one year postmenopausal) or if of child bearing potential, must be practicing effective double barrier contraceptive methods from at least two weeks prior to day 1 and until 30 days following cessation of dosing 8. Female subjects of childbearing potential must have a negative serum pregnancy test (beta human Chorionic Gonadotropin [beta-hCG]) at screening 9. Males must practice an effective barrier method of contraception from day 1 until 30 days following cessation of dosing 10. A physical examination must be without clinically significant findings with exception of those finding related to rheumatoid arthritis 11. At screening, Electrocardiogram (ECG) conduction intervals must be within the gender specific normal range (i.e., QTc for males less than 430 msec and females less than 450 msec) |
| Key exclusion criteria | 1. Individuals with a history of any significant medical disorder which require a physician's care (excluding rheumatoid arthritis) and would interfere with the study evaluations or compromise subject safety 2. Individuals who have a history of any clinically significant local or systemic infectious disease within four weeks prior to drug administration 3. Any subject with an allergy to gadolinium 4. Any subject with a pacemaker, metal object implanted their body or any other device or condition which may interfere with a subject's safety during the Magnetic Resonance Imaging (MRI) procedure 5. Any subject who has received Disease Modifying Anti-Rheumatic Drug (DMARD) treatment within 30 days prior to enrolment (leflunomide requires a charcoal or cholestyramine washout) 6. Any subject who has received anti-Tumour Necrotising Factor (anti-TNF) therapy (except enteracept) or any biologic therapy within the previous 90 days 7. Any subject whose baseline Disease Activity Score (DAS-28) has significantly changed since screening to indicate unstable disease 8. Any individual who does not comply with the requirement that he should not have used: 8.1. Any drugs (including herbal and mineral supplements or vitamins), other than acetaminophen or an approved stable regimen of low dose prednisone (10 mg/day) and/or Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), for at least two weeks prior to study drug administration 8.2. Alcohol in amounts of greater than 50 grams a day throughout the study 9. Subjects that have been diagnosed with Juvenile RA 10. A history of systemic lupus erythematosus, or signs and symptoms suggesting systemic lupus erythematosus 11. Subjects who are positive for hepatitis B surface antigen, hepatitis C Ribonucleic Acid (RNA) or for Human Immunodeficiency Virus (HIV) antibodies 12. Individuals who have participated in a clinical trial of an investigational drug within 90 days prior to the start of study drug administration, or have received prior treatment with a CCR5 receptor antagonist 13. Individuals with a positive screen for drugs of abuse 14. Individuals who have donated blood (greater than 300 mL) within the preceding 90 days 15. Males who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from study start until 30 days after the last study treatment 16. Females who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from two weeks prior to study start until 30 days after the last study treatment 17. Individuals who have received any vaccinations within 30 days prior to screening 18. Individuals with any clinically significant history of food or drug allergy or allergy to any component of SCH 351125 19. Subjects who are not willing to follow the study restrictions or procedures |
| Date of first enrolment | 01/03/2004 |
| Date of final enrolment | 01/05/2005 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Academic Medical Centre (AMC)
Amsterdam
1100 DD
Netherlands
1100 DD
Netherlands
Sponsor information
Schering Plough Research Institute (USA)
Industry
Industry
Schering-Plough Corporation Headquarters
2000 Galloping Hill Road
Kenilworth
New Jersey
07033-0530
United States of America
| Website | http://www.schering-plough.com/schering_plough/research/research_institute.jsp |
|---|---|
"ROR" |
https://ror.org/02891sr49 |
Funders
Funder type
Industry
Schering Plough Research Institute (USA)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
